2型糖尿病的疾病成本:叙述性回顾

Nadia Pramasari, D. Endarti, Anna Wahyuni Widayanti
{"title":"2型糖尿病的疾病成本:叙述性回顾","authors":"Nadia Pramasari, D. Endarti, Anna Wahyuni Widayanti","doi":"10.31603/pharmacy.v8i1.5958","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus (DM) is chronic disease that requires routine lifelong treatment. Uncontrolled blood sugar levels in DM patients can cause complications. This has an impact on the burden of health costs. The aim of this study to conduct a narrative review of the cost of illness in type 2 DM patients in various countries. The English articles used in this study were obtained from Pubmed, ScienceDirect, and Wiley that published in the period 2011 to 2021. The cost reported in the articles were local currency that later converted into US dollars according to the time of the study. Based on the narrative review, there are 19 articles that meet the criteria. In the article, there are varied perspectives, methods, and cost categories. The total cost per year for type 2 DM ranged from US$246.1 to US$5894.1, direct, and indirect costs per patient per year ranged from US$ 104.6 to US$5246.4 and US$82.9 to US$2299.4. Type 2 diabetes mellitus increases the burden of health costs. The presence of complications in type 2 DM patients requires higher health costs compared to uncomplicated type 2 DM patients and non-DM patient","PeriodicalId":17722,"journal":{"name":"Jurnal Farmasi Sains dan Praktis","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COST OF ILLNESS DIABETES MELITUS TIPE 2: NARRATIVE REVIEW\",\"authors\":\"Nadia Pramasari, D. Endarti, Anna Wahyuni Widayanti\",\"doi\":\"10.31603/pharmacy.v8i1.5958\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetes mellitus (DM) is chronic disease that requires routine lifelong treatment. Uncontrolled blood sugar levels in DM patients can cause complications. This has an impact on the burden of health costs. The aim of this study to conduct a narrative review of the cost of illness in type 2 DM patients in various countries. The English articles used in this study were obtained from Pubmed, ScienceDirect, and Wiley that published in the period 2011 to 2021. The cost reported in the articles were local currency that later converted into US dollars according to the time of the study. Based on the narrative review, there are 19 articles that meet the criteria. In the article, there are varied perspectives, methods, and cost categories. The total cost per year for type 2 DM ranged from US$246.1 to US$5894.1, direct, and indirect costs per patient per year ranged from US$ 104.6 to US$5246.4 and US$82.9 to US$2299.4. Type 2 diabetes mellitus increases the burden of health costs. The presence of complications in type 2 DM patients requires higher health costs compared to uncomplicated type 2 DM patients and non-DM patient\",\"PeriodicalId\":17722,\"journal\":{\"name\":\"Jurnal Farmasi Sains dan Praktis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jurnal Farmasi Sains dan Praktis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31603/pharmacy.v8i1.5958\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Farmasi Sains dan Praktis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31603/pharmacy.v8i1.5958","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

糖尿病是一种需要终生常规治疗的慢性疾病。糖尿病患者血糖水平失控会导致并发症。这对医疗费用负担产生了影响。本研究的目的是对各国2型糖尿病患者的疾病成本进行叙述性回顾。本研究中使用的英文文章来自Pubmed、ScienceDirect和Wiley,发表于2011年至2021年。文章中报告的成本是当地货币,后来根据研究时间转换为美元。根据叙述性审查,有19篇文章符合标准。在这篇文章中,有不同的视角、方法和成本类别。2型糖尿病每年的总费用为246.1美元至5894.1美元,每位患者每年的直接和间接费用为104.6美元至5246.4美元,82.9美元至2299.4美元。2型糖尿病增加了医疗费用负担。与无并发症的2型糖尿病患者和非糖尿病患者相比,2型糖尿病病人存在并发症需要更高的医疗费用
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COST OF ILLNESS DIABETES MELITUS TIPE 2: NARRATIVE REVIEW
Diabetes mellitus (DM) is chronic disease that requires routine lifelong treatment. Uncontrolled blood sugar levels in DM patients can cause complications. This has an impact on the burden of health costs. The aim of this study to conduct a narrative review of the cost of illness in type 2 DM patients in various countries. The English articles used in this study were obtained from Pubmed, ScienceDirect, and Wiley that published in the period 2011 to 2021. The cost reported in the articles were local currency that later converted into US dollars according to the time of the study. Based on the narrative review, there are 19 articles that meet the criteria. In the article, there are varied perspectives, methods, and cost categories. The total cost per year for type 2 DM ranged from US$246.1 to US$5894.1, direct, and indirect costs per patient per year ranged from US$ 104.6 to US$5246.4 and US$82.9 to US$2299.4. Type 2 diabetes mellitus increases the burden of health costs. The presence of complications in type 2 DM patients requires higher health costs compared to uncomplicated type 2 DM patients and non-DM patient
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
70
审稿时长
12 weeks
期刊最新文献
APPLICATION OF LAKES SYSTEM IN PREPARATION OF HAIR DYES POMADE CREAM OF FREEZE-DRIED RED DRAGON (Hylocereus polyrhizus) FRUIT PEEL JUICE AND ACUTE DERMAL IRRITATION SUN PROTECTION FACTOR (SPF) VALUE AND PHYSICAL PROPERTIES OF PURIFIED GAMBIER GEL PREPARATION TRACING THE ANTIBACTERIAL, ANTIFUNGAL AND ANTI-BIOFILM ACTIVITIES OF ROOT EXTRACT BAJAKAH TAMPALA (SPATHOLOBUS LITTORALIS HASSK) POTENTIAL KETAPANG (Terminalia cattapa) LEAF EXTRACT AS A DOXORUBICIN CO-CHEMOTHERAPY AGENT ON BREAST (T47D) AND CERVIX (HeLa) CANCER CELL LINES OPTIMIZATION OF DICLOFENAC POTASSIUM TRANSDERMAL PATCH FORMULA USING A COMBINATION OF POLYVYNIL PYRROLIDONE K 30, ETHYL CELLULOSE AND MENTHOL WITH SIMPLEX LATTICE DESIGN METHOD
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1